FDA Approves 6-Month Primary End Point for the Lutonix® Below-the-Knee Drug Coated Balloon

MURRAY HILL, N.J.--(BUSINESS WIRE)--C. R. Bard, Inc. (NYSE: BCR) today announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption (IDE) supplemental application to modify the primary endpoint to a 6-month time point for the Lutonix^® 014 Drug Coated Balloon PTA Catheter (DCB). The Lutonix^® 014 device is currently the only DCB in an IDE clinical trial in the U.S. for treatment of arteries below the knee (BTK).

The clinical trial is evaluating the device when used for the treatment of stenosis or occlusion of native BTK arteries with a cumulative lesion length up to 320 mm with reference vessel diameters of 2 to 4 mm. Currently, the study has enrolled approximately 340 patients, of which 69% are diabetic, 33% are female, and 95% have critical limb ischemia (CLI). The primary safety end point in the study is freedom from major adverse limb event or postoperative death at 30 days and the primary efficacy end point is a composite of limb salvage and primary patency at 6 months. An independent data monitoring committee, which is chartered to review patient safety for the study, has met for the tenth time and unanimously recommended continuation of the study with no modifications.

Similar to the Lutonix^® 035 DCB, the first drug coated balloon approved in the U.S., the Lutonix^® 014 DCB is an angioplasty balloon that is coated with a low dose of the drug paclitaxel, and also utilizes standard mechanical dilatation of the vessel to restore blood flow for patients with peripheral arterial disease (PAD). The Lutonix^® 035 DCB is also the only DCB being evaluated in an IDE trial for the treatment of dysfunctional arteriovenous fistulae located in the upper extremity.

PAD is estimated to be present in 3% of people in the age range of 40 to 59 years and in 20% of people over 70 years¹ of age. The majority of patients undergoing BTK interventions suffer from CLI with high cardiovascular risk and often significant medical co-morbidities. CLI is typically defined as limb pain that occurs at rest (Rutherford Category 4)², or impending limb loss that is caused by severely compromised blood flow to the affected extremity leading to non-healing ulcers (Rutherford Category 5 and 6).

“Below the knee PAD is a challenging disease in a patient group that is currently under served. Patients often have to undergo frequent reinterventions following initial treatment. Regular balloon angioplasty is the primary catheter-based treatment option available today” said Dr. Michael R. Jaff, Medical Director of VasCore, the vascular ultrasound core laboratory used in the Lutonix^® BTK trial.

“A significant number of patients with BTK disease are at risk of limb loss and would be expected to benefit from alternative treatment options. The Lutonix^® 014 DCB could offer physicians an opportunity to change the treatment paradigm for patients by providing a safe and effective method to deliver paclitaxel directly to stenosed BTK vessels,” said Jihad Mustapha, M.D., Lutonix^® BTK Principal Investigator.

The Lutonix^® 014 DCB has been available commercially in Europe since 2013 and is available in most geographies outside the U.S. In the U.S., the Lutonix^® 014 DCB is currently an investigational device limited by U.S. law to investigational use.

^1	Zeller, T. Current state of endovascular treatment of femoro-popliteal artery disease. Vas Med 12 (2007): 223-234.
^2	Rutherford RB, Baker JD, Ernst C, Johnston KW, Porter JM, Ahn S, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26:517-38.

C. R. Bard, Inc. (www.crbard.com), headquartered in Murray Hill, NJ, is a leading multinational developer, manufacturer and marketer of innovative, life-enhancing medical technologies in the fields of vascular, urology, oncology and surgical specialty products.

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current expectations, the accuracy of which is necessarily subject to risks and uncertainties. These statements are not historical in nature and use words such as “anticipate”, “estimate”, “expect”, “project”, “intend”, “forecast”, “plan”, “believe”, and other words of similar meaning in connection with any discussion of future operating or financial performance. Many factors may cause actual results to differ materially from anticipated results including product developments, sales efforts, income tax matters, the outcomes of contingencies such as legal proceedings, and other economic, business, competitive and regulatory factors. The company undertakes no obligation to update its forward-looking statements. Please refer to the Cautionary Statement Regarding Forward-Looking Information in our June 30, 2016 Form 10-Q for more detailed information about these and other factors that may cause actual results to differ materially from those expressed or implied.